Key clinical point: A novel, five-item metric of patient-centered TAVR outcomes showed excellent performance and validity.
Major finding: When applied to 301 U.S. programs the metric identified 34 (11%) underperforming programs and 25 (8%) overperforming programs.
Study details: Researchers derived the metric with data from 52,561 U.S. transfemoral TAVR patients treated during 2015-2017.
Disclosures: The STS/ACC TVT Registry receives no commercial funding. Dr. Desai has been a consultant to, speaker on behalf of, and received research funding from Gore, and he has also spoken on behalf of Cook, Medtronic, and Terumo Aortic. Dr. Cleveland, Dr. Mack, and Dr. Pershad had no disclosures.
Desai ND. ACC 20, Abstract 405-12.